ARTICLE | Clinical News
Zalutumumab: Phase III data
March 15, 2010 7:00 AM UTC
Top-line data from a Phase III trial in 286 patients showed that zalutumumab plus best supportive care missed the primary endpoint of significantly increasing median OS vs. best supportive care alone ...